These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 38070788)

  • 1. Functional pri-miR-34b/c rs4938723 and KRAS 3'UTR rs61764370 SNPs: Novel phenotype modifiers in Li-Fraumeni Syndrome?
    Vieira IA; Pezzi EH; Bandeira IC; Reis LB; de Araújo Rocha YM; Fernandes BV; Siebert M; Miyamoto KN; Siqueira MB; Achatz MI; Galvão HCR; Garcia FAO; Campacci N; Carraro DM; Formiga MN; Vianna FSL; Palmero EI; Macedo GS; Ashton-Prolla P
    Gene; 2024 Mar; 898():148069. PubMed ID: 38070788
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Li-Fraumeni and Li-Fraumeni-like syndrome among children diagnosed with pediatric cancer in Southern Brazil.
    Giacomazzi J; Selistre SG; Rossi C; Alemar B; Santos-Silva P; Pereira FS; Netto CB; Cossio SL; Roth DE; Brunetto AL; Zagonel-Oliveira M; Martel-Planche G; Goldim JR; Hainaut P; Camey SA; Ashton-Prolla P
    Cancer; 2013 Dec; 119(24):4341-9. PubMed ID: 24122735
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MIR605 rs2043556 is associated with the occurrence of multiple primary tumors in TP53 p.(Arg337His) mutation carriers.
    Bandeira IC; Vieira IA; Andreis TF; Brussa Reis L; Macedo GS; Vianna FSL; Santos-Silva P; Palmero EI; Galvão HCR; Ramos CRN; Santiago KM; Achatz MI; da Costa AABA; Ashton-Prolla P
    Cancer Genet; 2020 Jan; 240():54-58. PubMed ID: 31778928
    [TBL] [Abstract][Full Text] [Related]  

  • 4. p53 signaling pathway polymorphisms, cancer risk and tumor phenotype in TP53 R337H mutation carriers.
    Macedo GS; Vieira IA; Vianna FSL; Alemar B; Giacomazzi J; Brandalize APC; Caleffi M; Volc SM; de Campos Reis Galvão H; Palmero EI; Achatz MI; Ashton-Prolla P
    Fam Cancer; 2018 Apr; 17(2):269-274. PubMed ID: 28756477
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical spectrum of Li-Fraumeni syndrome/Li-Fraumeni-like syndrome in Brazilian individuals with the TP53 p.R337H mutation.
    Ferreira AM; Brondani VB; Helena VP; Charchar HLS; Zerbini MCN; Leite LAS; Hoff AO; Latronico AC; Mendonca BB; Diz MDPE; de Almeida MQ; Fragoso MCBV
    J Steroid Biochem Mol Biol; 2019 Jun; 190():250-255. PubMed ID: 30974190
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A functional variant in miR-605 modifies the age of onset in Li-Fraumeni syndrome.
    Id Said B; Malkin D
    Cancer Genet; 2015; 208(1-2):47-51. PubMed ID: 25683625
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Frequency of Thyroid Carcinoma in Brazilian TP53 p.R337H Carriers With Li Fraumeni Syndrome.
    Formiga MNDC; de Andrade KC; Kowalski LP; Achatz MI
    JAMA Oncol; 2017 Oct; 3(10):1400-1402. PubMed ID: 28114597
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical and molecular characterization of patients fulfilling Chompret criteria for Li-Fraumeni syndrome in Southern Brazil.
    Matzenbacher Bittar C; de Araújo Rocha YM; Vieira IA; Rosset C; Andreis TF; Sartor ITS; Artigalás O; Netto CBO; Alemar B; Macedo GS; Ashton-Prolla P
    PLoS One; 2021; 16(9):e0251639. PubMed ID: 34529667
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Li-Fraumeni syndrome in Tunisian carriers with different and rare tumor phenotype: genotype-phenotype correlation.
    Sassi H; Meddeb R; Cherif MA; Nasr C; Riahi A; Hannachi S; Belguith N; M'rad R
    BMC Med Genomics; 2022 Mar; 15(1):44. PubMed ID: 35246108
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined analysis of pri-miR-34b/c rs4938723 and TP53 Arg72Pro with cervical cancer risk.
    Yuan F; Sun R; Chen P; Liang Y; Ni S; Quan Y; Huang J; Zhang L; Gao L
    Tumour Biol; 2016 May; 37(5):6267-73. PubMed ID: 26619844
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The TP53 mutation, R337H, is associated with Li-Fraumeni and Li-Fraumeni-like syndromes in Brazilian families.
    Achatz MI; Olivier M; Le Calvez F; Martel-Planche G; Lopes A; Rossi BM; Ashton-Prolla P; Giugliani R; Palmero EI; Vargas FR; Da Rocha JC; Vettore AL; Hainaut P
    Cancer Lett; 2007 Jan; 245(1-2):96-102. PubMed ID: 16494995
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of TP53 rs1042522 C>G and miR-34b/c rs4938723 T>C polymorphisms with hepatoblastoma susceptibility: A seven-center case-control study.
    Liu P; Zhuo ZJ; Zhu J; Yang Z; Xin Y; Li S; Li L; Li Y; Wang H; He J
    J Gene Med; 2020 Jul; 22(7):e3182. PubMed ID: 32166848
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TP53 p.R337H is a conditional cancer-predisposing mutation: further evidence from a homozygous patient.
    Giacomazzi J; Selistre S; Duarte J; Ribeiro JP; Vieira PJ; de Souza Macedo G; Rossi C; Czepielewski M; Netto CB; Hainaut P; Ashton-Prolla P
    BMC Cancer; 2013 Apr; 13():187. PubMed ID: 23570263
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pri-miR-34b/c rs4938723 Polymorphism Contributes to Coronary Artery Disease Susceptibility.
    Cen J; Xiong Q; Yang X; Guo J; Xiong XD; Zhang A
    Arch Med Res; 2019 May; 50(4):170-174. PubMed ID: 31499476
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of TP53 Pro72Arg and MDM2 SNP285-SNP309 polymorphisms in an Italian cohort of LFS suggestive patients lacking identifiable TP53 germline mutations.
    Ponti F; Corsini S; Gnoli M; Pedrini E; Mordenti M; Sangiorgi L
    Fam Cancer; 2016 Oct; 15(4):635-43. PubMed ID: 26956143
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rare germline variant (rs78378222) in the TP53 3' UTR: Evidence for a new mechanism of cancer predisposition in Li-Fraumeni syndrome.
    Macedo GS; Araujo Vieira I; Brandalize AP; Giacomazzi J; Inez Palmero E; Volc S; Rodrigues Paixão-Côrtes V; Caleffi M; Silva Alves M; Achatz MI; Hainaut P; Ashton-Prolla P
    Cancer Genet; 2016 Mar; 209(3):97-106. PubMed ID: 26823150
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of the Li-Fraumeni Spectrum Based on an International Germline TP53 Variant Data Set: An International Agency for Research on Cancer TP53 Database Analysis.
    Kratz CP; Freycon C; Maxwell KN; Nichols KE; Schiffman JD; Evans DG; Achatz MI; Savage SA; Weitzel JN; Garber JE; Hainaut P; Malkin D
    JAMA Oncol; 2021 Dec; 7(12):1800-1805. PubMed ID: 34709361
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of the
    Sandoval RL; Masotti C; de Macedo MP; Ribeiro MFSA; Leite ACR; Meireles SI; Bovolin RM; Santini FC; Munhoz RR; Jardim DLF; Katz A; Camargo AA; Fernandes GDS; Achatz MI
    JCO Glob Oncol; 2021 Jul; 7():1141-1150. PubMed ID: 34270331
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TP53 and CDKN1A mutation analysis in families with Li-Fraumeni and Li-Fraumeni like syndromes.
    Andrade RC; Dos Santos AC; de Aguirre Neto JC; Nevado J; Lapunzina P; Vargas FR
    Fam Cancer; 2017 Apr; 16(2):243-248. PubMed ID: 27714481
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    Corrêa TS; Asprino PF; de Oliveira ESC; Leite ACR; Weis L; Achatz MI; de Oliveira CP; Sandoval RL; Barroso-Sousa R
    Genes (Basel); 2024 Jul; 15(7):. PubMed ID: 39062707
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.